Hybridization for Human Epidermal Growth Factor Receptor 2 Testing in Gastric Carcinoma: a Comparison of Fluorescence In-situ Hybridization with a Novel Fully Automated Dual-colour Silver In-situ Hybridization Method

Overview

Journal Histopathology

Specialties Anatomy & Histology
Pathology

Date 2011 Jul 21

PMID 21771023

Citations 15

Authors

Elena Garcia-Garcia

Carlos Gomez-Martin

Barbara Angulo

Esther Conde

Ana Suarez-Gauthier

Magdalena Adrados

Cristian Perna

Jose Luis Rodriguez-Peralto

Manuel Hidalgo

Fernando Lopez-Rios

Affiliations

Soon will be listed here.

Abstract

Aims: Amplification of the human epidermal growth factor receptor 2 (HER2) gene has been reported in gastric carcinoma (GC). Accordingly, trastuzumab plus chemotherapy has recently become the new standard treatment for HER2-positive advanced GCs. The aim was to compare the alleged gold standard for hybridization [fluorescence in-situ hybridization (FISH)] with a novel, fully automated brightfield dual-colour silver-enhanced in-situ hybridization (SISH) method.

Methods And Results: The studies series was comprised of 166 GC samples. Additionally, tumours with discordant results obtained by FISH and SISH were analysed by real-time quantitative polymerase chain reaction (PCR) with the LightMix kit HER-2/neu. Of the samples, 17.5% and 21% were amplified by FISH and SISH, respectively. Heterogeneity was identified in up to 52% of cases. In 96.4% of cases, FISH showed the same results as SISH. All six discordant cases were positive by SISH and negative by FISH. On review of the FISH slides, all contradictory cases were polysomic and were confirmed to be negative for amplification by real-time PCR. Interestingly, all ratios in this latter group were between 2.06 and 2.50, so setting the cut-off for amplification at ≥3 resulted in perfect concordance.

Conclusions: Dual-colour SISH represents a novel method for the determination of HER2 status in GC.

Citing Articles

Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues.

Wang S, Wang Y, Zhu C, Jiang B, Ge D, Li Y Clin Transl Oncol. 2024; 27(1):126-134.

PMID: 38907827 DOI: 10.1007/s12094-024-03534-0.

Association of HER2 gene amplification and tumor progression in early gastric cancer.

Kanayama K, Imai H, Usugi E, Shiraishi T, Hirokawa Y, Watanabe M Virchows Arch. 2018; 473(5):559-565.

PMID: 30120594 DOI: 10.1007/s00428-018-2433-y.

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

Diaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jimenez-Fonseca P Oncologist. 2018; 23(9):1092-1102.

PMID: 29700210 PMC: 6192610. DOI: 10.1634/theoncologist.2017-0379.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley A, Washington M, Ventura C, Ismaila N, Colasacco C, Benson 3rd A Am J Clin Pathol. 2017; 146(6):647-669.

PMID: 28077399 PMC: 6272805. DOI: 10.1093/ajcp/aqw206.

Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.

Kanayama K, Imai H, Yoneda M, Hirokawa Y, Shiraishi T Cancer Sci. 2016; 107(4):536-42.

PMID: 26752196 PMC: 4832862. DOI: 10.1111/cas.12886.

References

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Garcia-Caballero T, Grabau D, Green A, Gregory J, Schad A, Kohlwes E . Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology. 2010; 56(4):472-80. PMC: 2855864. DOI: 10.1111/j.1365-2559.2010.03503.x. View

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo A, Gaire F, Farrell M . Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ.... Diagn Pathol. 2008; 3:41. PMC: 2577627. DOI: 10.1186/1746-1596-3-41. View

Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A . Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2009; 21(4):815-819. PMC: 2844947. DOI: 10.1093/annonc/mdp488. View

Mass R, Press M, Anderson S, Cobleigh M, Vogel C, Dybdal N . Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005; 6(3):240-6. DOI: 10.3816/CBC.2005.n.026. View

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B . Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology. 2009; 54(2):248-53. DOI: 10.1111/j.1365-2559.2008.03185.x. View

Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X . Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008; 8:363. PMC: 2613415. DOI: 10.1186/1471-2407-8-363. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

10.

Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs D . Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol. 2008; 21(4):363-8. DOI: 10.1038/modpathol.3801021. View

11.

Tubbs R, Pettay J, Roche P, Stoler M, Jenkins R, Grogan T . Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001; 19(10):2714-21. DOI: 10.1200/JCO.2001.19.10.2714. View

12.

Phillips K, Marshall D, Haas J, Elkin E, Liang S, Hassett M . Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009; 115(22):5166-74. PMC: 2783254. DOI: 10.1002/cncr.24574. View

13.

Barros-Silva J, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M . Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009; 100(3):487-93. PMC: 2658544. DOI: 10.1038/sj.bjc.6604885. View

14.

Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio M . Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008; 10(6):527-36. PMC: 2570636. DOI: 10.2353/jmoldx.2008.080052. View

15.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

16.

Kanta S, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A . Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006; 37(10):1333-43. DOI: 10.1016/j.humpath.2006.05.008. View

17.

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

18.

Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A . Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003; 16(2):173-82. DOI: 10.1097/01.MP.0000052102.90815.82. View

19.

Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M . A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010; 12(3):292-9. PMC: 2860464. DOI: 10.2353/jmoldx.2010.090139. View

20.

Salto-Tellez M, Yau E, Yan B, Fox S . Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. Arch Pathol Lab Med. 2011; 135(6):693-5. DOI: 10.5858/2011-0084-ED.1. View